论文部分内容阅读
世纪之交,国家颁布的药品生产质量管理规模,可能令很多药厂被淘汰,却可能是另外一些药厂的商机。香港协和集团董事总经理、太平协和主席汪世忠的兄长汪世华就以这个新规定为切入点,全力发展药业市场,在四川收购了三家药品及药业用具厂。他认为,中国药业已有几千年历史,但近20年的发展却是空前的,成就可能超越过去几千年的发展。太平协和集团在国内有很多投资,包括地产、石油、电讯、零售等,但投资药业却是最近的事,这项业务正是由汪世华负责打理。他深信,投资中国药业可获得极为理想的回报:“中国经历改革开放,
At the turn of the century, the scale of pharmaceutical production quality management promulgated by the state may cause many pharmaceutical companies to be eliminated, but it may be a business opportunity for other pharmaceutical companies. Wang Shihua, the managing director of Hong Kong Concord Group and the brother of Wang Shizhong, chairman of Taiping Xiehe, took this new requirement as an entry point, made every effort to develop the pharmaceutical market, and acquired three pharmaceutical and pharmaceutical appliance factories in Sichuan. He believes that China’s pharmaceutical industry has a history of thousands of years, but the development in the past 20 years is unprecedented, and the achievements may surpass the development of the past few thousand years. Taiping Xiehe Group has a lot of investment in China, including real estate, petroleum, telecommunications, retail, etc. However, investing in the pharmaceutical industry is the latest thing. This business is handled by Wang Shihua. He is convinced that investing in the Chinese pharmaceutical industry can be extremely rewarding: ”China has undergone reform and opening up."